erlotinib

Compounds 12, 17, 27, 43, 45, and 49 demonstrated strong binding affinities and superior pharmacokinetic profiles compared to Gefitinib and Erlotinib. Overall, benzothiazole derivatives represent a promising scaffold for the design of EGFR inhibitors, potentially contributing to targeted anticancer therapy.

P=N/A, N=4864, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Nov 2025 | Trial primary completion date: Jan 2025 --> Nov 2025

This in silico study predicts Carteolol as a potential dual-targeting therapeutic agent, requiring biochemical and cellular validation before clinical relevance can be established.

P2, N=168, Completed, Eli Lilly and Company | Active, not recruiting --> Completed

P1, N=85, Active, not recruiting, Boundless Bio | Recruiting --> Active, not recruiting | N=127 --> 85

Compounds 4a and 4g were the most potent EGFR inhibitors (IC50  = 0.09 µM and 0.10 µM, respectively), compared to the standard erlotinib (IC50 = 0.16 µM)...This binding interaction likely contributes to their significant biological activity. Further, dynamic stimulation study that is conducted for compounds 4a and 4g, supports their potency as therapeutic agents in cancer treatment.

Our study established a NM-related gene signature closely linked to immune microenvironment and drug sensitivity, highlighting potential biomarkers and therapeutic targets for prognosis and personalized therapy in HNSCC.

Cassia-derived flavonoids represent promising multi-target candidates for lung cancer therapy, particularly through modulation of PTGS2, KIT, and XDH. Their favorable interaction profiles and safety predictions warrant further experimental and in vivo validation.

The binding affinities of cianidanol and Leucocianidol were the highest, - 8.8 kcal/mol and - 8.7 kcal/mol respectively, as compared to the reference drug erlotinib which has a binding affinity of - 8.3 kcal/Mol...The studies suggests that EGFR is strongly bound by B. ciliata phytochemicals, and their biocompatible profiles are safer and more inclined to biocompatibility compared to the conventional inhibitor. These findings have indicated that these compounds can be useful lead scaffolds in the development of anticancer drugs in future as they have been shown to possess promising properties that would be further validated by studies conducted in in vitro and in vivo.

Compounds 10c, 10e, 10k, 10m, 10n, and 10o exhibited superior anticancer efficacy against the evaluated cancer cell lines, demonstrating a favorable safety profile, particularly against MCF-7 breast cancer, compared to erlotinib...The most potent compounds demonstrated drug-like properties and could serve as prototypes for future optimization. Compounds 10e and 10k may serve as examples of multi-targeting anticancer agents that function by blocking the EGFR, HER-2, and VEGFR-2 kinases.

P3, N=545, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2025 --> Dec 2026

The compound 2j significantly inhibited the MDA-MB-231 cells proliferation by downregulation of EGFR, p-EGFR, and p-AKT protein expression levels. Molecular docking studies revealed that compound 2j had a strong binding affinity and interacted closely with key catalytic residues of EGFR, outperforming erlotinib, a known EGFR inhibitor, suggesting its potential as an anti-breast cancer drug candidate.